vs
Side-by-side financial comparison of COMERICA INC (CMA) and BeOne Medicines Ltd. (ONC). Click either name above to swap in a different company.
BeOne Medicines Ltd. is the larger business by last-quarter revenue ($1.5B vs $838.0M, roughly 1.8× COMERICA INC). COMERICA INC runs the higher net margin — 21.0% vs 4.4%, a 16.6% gap on every dollar of revenue. On growth, BeOne Medicines Ltd. posted the faster year-over-year revenue change (32.8% vs 3.3%). Over the past eight quarters, COMERICA INC's revenue compounded faster (108.9% CAGR vs 41.2%).
Comerica Incorporated is an American financial services company, headquartered in Dallas, Texas. It is the parent of Comerica Bank, a regional commercial bank with 413 branches in the U.S. states of Texas, Michigan, California, Florida and Arizona. Comerica is among the largest U.S. financial holding companies, with offices in a number of U.S. cities.
BeOne Medicines Ltd.ONCEarnings & Financial Report
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
CMA vs ONC — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $838.0M | $1.5B |
| Net Profit | $176.0M | $66.5M |
| Gross Margin | — | 90.5% |
| Operating Margin | — | 12.4% |
| Net Margin | 21.0% | 4.4% |
| Revenue YoY | 3.3% | 32.8% |
| Net Profit YoY | -4.3% | 143.8% |
| EPS (diluted) | $1.35 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $1.5B | ||
| Q3 25 | $838.0M | $1.4B | ||
| Q2 25 | $849.0M | $1.3B | ||
| Q1 25 | $829.0M | $1.1B | ||
| Q4 24 | $825.0M | $1.1B | ||
| Q3 24 | $811.0M | $1.0B | ||
| Q2 24 | $824.0M | $929.2M | ||
| Q1 24 | $784.0M | $751.7M |
| Q4 25 | — | $66.5M | ||
| Q3 25 | $176.0M | $124.8M | ||
| Q2 25 | $199.0M | $94.3M | ||
| Q1 25 | $172.0M | $1.3M | ||
| Q4 24 | $170.0M | $-151.9M | ||
| Q3 24 | $184.0M | $-121.3M | ||
| Q2 24 | $206.0M | $-120.4M | ||
| Q1 24 | $138.0M | $-251.2M |
| Q4 25 | — | 90.5% | ||
| Q3 25 | — | 86.1% | ||
| Q2 25 | — | 87.5% | ||
| Q1 25 | — | 85.2% | ||
| Q4 24 | — | 85.8% | ||
| Q3 24 | — | 83.0% | ||
| Q2 24 | — | 85.1% | ||
| Q1 24 | — | 83.4% |
| Q4 25 | — | 12.4% | ||
| Q3 25 | — | 11.5% | ||
| Q2 25 | — | 6.7% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | -7.0% | ||
| Q3 24 | — | -12.0% | ||
| Q2 24 | — | -11.5% | ||
| Q1 24 | — | -34.8% |
| Q4 25 | — | 4.4% | ||
| Q3 25 | 21.0% | 8.8% | ||
| Q2 25 | 23.4% | 7.2% | ||
| Q1 25 | 20.7% | 0.1% | ||
| Q4 24 | 20.6% | -13.5% | ||
| Q3 24 | 22.7% | -12.1% | ||
| Q2 24 | 25.0% | -13.0% | ||
| Q1 24 | 17.6% | -33.4% |
| Q4 25 | — | $0.05 | ||
| Q3 25 | $1.35 | $0.08 | ||
| Q2 25 | $1.42 | $0.06 | ||
| Q1 25 | $1.25 | $0.00 | ||
| Q4 24 | $1.22 | $-0.10 | ||
| Q3 24 | $1.33 | $-0.09 | ||
| Q2 24 | $1.49 | $-0.09 | ||
| Q1 24 | $0.98 | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $4.5B |
| Total DebtLower is stronger | $5.4B | $836.4M |
| Stockholders' EquityBook value | $7.4B | $4.4B |
| Total Assets | $77.4B | $8.2B |
| Debt / EquityLower = less leverage | 0.73× | 0.19× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $4.5B | ||
| Q3 25 | — | $4.0B | ||
| Q2 25 | — | $2.8B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | — | $2.6B | ||
| Q3 24 | — | $2.7B | ||
| Q2 24 | — | $2.6B | ||
| Q1 24 | — | $2.8B |
| Q4 25 | — | $836.4M | ||
| Q3 25 | $5.4B | — | ||
| Q2 25 | $5.8B | — | ||
| Q1 25 | $5.7B | — | ||
| Q4 24 | $6.7B | — | ||
| Q3 24 | $6.8B | — | ||
| Q2 24 | $7.1B | — | ||
| Q1 24 | $7.1B | — |
| Q4 25 | — | $4.4B | ||
| Q3 25 | $7.4B | $4.1B | ||
| Q2 25 | $6.9B | $3.8B | ||
| Q1 25 | $7.1B | $3.5B | ||
| Q4 24 | $6.5B | $3.3B | ||
| Q3 24 | $7.4B | $3.4B | ||
| Q2 24 | $6.2B | $3.4B | ||
| Q1 24 | $6.0B | $3.4B |
| Q4 25 | — | $8.2B | ||
| Q3 25 | $77.4B | $7.6B | ||
| Q2 25 | $78.0B | $6.3B | ||
| Q1 25 | $77.6B | $5.8B | ||
| Q4 24 | $79.3B | $5.9B | ||
| Q3 24 | $79.7B | $5.8B | ||
| Q2 24 | $79.6B | $5.7B | ||
| Q1 24 | $79.4B | $5.7B |
| Q4 25 | — | 0.19× | ||
| Q3 25 | 0.73× | — | ||
| Q2 25 | 0.84× | — | ||
| Q1 25 | 0.81× | — | ||
| Q4 24 | 1.02× | — | ||
| Q3 24 | 0.92× | — | ||
| Q2 24 | 1.15× | — | ||
| Q1 24 | 1.18× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-270.0M | $417.3M |
| Free Cash FlowOCF − Capex | — | $379.8M |
| FCF MarginFCF / Revenue | — | 25.4% |
| Capex IntensityCapex / Revenue | — | 2.5% |
| Cash ConversionOCF / Net Profit | -1.53× | 6.28× |
| TTM Free Cash FlowTrailing 4 quarters | — | $941.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $417.3M | ||
| Q3 25 | $-270.0M | $402.6M | ||
| Q2 25 | $476.0M | $263.6M | ||
| Q1 25 | $273.0M | $44.1M | ||
| Q4 24 | $601.0M | $75.2M | ||
| Q3 24 | $1.0B | $188.4M | ||
| Q2 24 | $111.0M | $-95.6M | ||
| Q1 24 | $-205.0M | $-308.6M |
| Q4 25 | — | $379.8M | ||
| Q3 25 | — | $354.5M | ||
| Q2 25 | — | $219.8M | ||
| Q1 25 | — | $-12.3M | ||
| Q4 24 | — | $-17.3M | ||
| Q3 24 | — | $54.7M | ||
| Q2 24 | — | $-205.5M | ||
| Q1 24 | — | $-465.1M |
| Q4 25 | — | 25.4% | ||
| Q3 25 | — | 25.1% | ||
| Q2 25 | — | 16.7% | ||
| Q1 25 | — | -1.1% | ||
| Q4 24 | — | -1.5% | ||
| Q3 24 | — | 5.5% | ||
| Q2 24 | — | -22.1% | ||
| Q1 24 | — | -61.9% |
| Q4 25 | — | 2.5% | ||
| Q3 25 | — | 3.4% | ||
| Q2 25 | — | 3.3% | ||
| Q1 25 | — | 5.0% | ||
| Q4 24 | — | 8.2% | ||
| Q3 24 | — | 13.3% | ||
| Q2 24 | — | 11.8% | ||
| Q1 24 | — | 20.8% |
| Q4 25 | — | 6.28× | ||
| Q3 25 | -1.53× | 3.22× | ||
| Q2 25 | 2.39× | 2.79× | ||
| Q1 25 | 1.59× | 34.71× | ||
| Q4 24 | 3.54× | — | ||
| Q3 24 | 5.70× | — | ||
| Q2 24 | 0.54× | — | ||
| Q1 24 | -1.49× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
